Endoluminal weight loss and metabolic therapies: current and future techniques

Research output: Contribution to journalReview article

Abstract

Obesity is a public health epidemic associated with a number of comorbidities, most notably type 2 diabetes and hypertension, as well as elevated all-cause mortality. The treatment for obesity and its associated comorbidities has most recently expanded into the field of bariatric endoscopy. This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Because of its minimally invasive nature, bariatric endoscopic therapy has the potential to appeal to the large sector of the obese population that resists surgery, as well as those early in the onset of obesity. To date, five endoscopic devices have been approved by the U.S. Food and Drug Administration for the treatment of obesity, and many more are in development, undergoing clinical trials, or being used around the world. Here, we present the current state of the field, highlight recent developments, and describe the clinical outcomes of these minimally invasive procedures in terms of weight loss, improvement in metabolic profile, and reduction in comorbidities.

Original languageEnglish (US)
Pages (from-to)36-52
Number of pages17
JournalAnnals of the New York Academy of Sciences
Volume1411
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Surgery
Weight Loss
Obesity
Endoscopy
Public health
Bariatrics
Comorbidity
Medical problems
Therapeutics
Pharmaceutical Preparations
Bariatric Surgery
Metabolome
United States Food and Drug Administration
Type 2 Diabetes Mellitus
Life Style
Counseling
Public Health
Therapy
Clinical Trials
Hypertension

Keywords

  • aspiration therapy
  • endoscopic sleeve gastroplasty
  • gastrointestinal bypass sleeve
  • intragastric balloon
  • primary obesity surgery endoluminal
  • transoral gastroplasty

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Endoluminal weight loss and metabolic therapies : current and future techniques. / Hill, Christine; Khashab, Mouen; Kalloo, Anthony N; Kumbhari, Vivek.

In: Annals of the New York Academy of Sciences, Vol. 1411, No. 1, 01.01.2018, p. 36-52.

Research output: Contribution to journalReview article

@article{7a59f8b72f524e6c882b15741446416d,
title = "Endoluminal weight loss and metabolic therapies: current and future techniques",
abstract = "Obesity is a public health epidemic associated with a number of comorbidities, most notably type 2 diabetes and hypertension, as well as elevated all-cause mortality. The treatment for obesity and its associated comorbidities has most recently expanded into the field of bariatric endoscopy. This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Because of its minimally invasive nature, bariatric endoscopic therapy has the potential to appeal to the large sector of the obese population that resists surgery, as well as those early in the onset of obesity. To date, five endoscopic devices have been approved by the U.S. Food and Drug Administration for the treatment of obesity, and many more are in development, undergoing clinical trials, or being used around the world. Here, we present the current state of the field, highlight recent developments, and describe the clinical outcomes of these minimally invasive procedures in terms of weight loss, improvement in metabolic profile, and reduction in comorbidities.",
keywords = "aspiration therapy, endoscopic sleeve gastroplasty, gastrointestinal bypass sleeve, intragastric balloon, primary obesity surgery endoluminal, transoral gastroplasty",
author = "Christine Hill and Mouen Khashab and Kalloo, {Anthony N} and Vivek Kumbhari",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/nyas.13441",
language = "English (US)",
volume = "1411",
pages = "36--52",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Endoluminal weight loss and metabolic therapies

T2 - current and future techniques

AU - Hill, Christine

AU - Khashab, Mouen

AU - Kalloo, Anthony N

AU - Kumbhari, Vivek

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Obesity is a public health epidemic associated with a number of comorbidities, most notably type 2 diabetes and hypertension, as well as elevated all-cause mortality. The treatment for obesity and its associated comorbidities has most recently expanded into the field of bariatric endoscopy. This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Because of its minimally invasive nature, bariatric endoscopic therapy has the potential to appeal to the large sector of the obese population that resists surgery, as well as those early in the onset of obesity. To date, five endoscopic devices have been approved by the U.S. Food and Drug Administration for the treatment of obesity, and many more are in development, undergoing clinical trials, or being used around the world. Here, we present the current state of the field, highlight recent developments, and describe the clinical outcomes of these minimally invasive procedures in terms of weight loss, improvement in metabolic profile, and reduction in comorbidities.

AB - Obesity is a public health epidemic associated with a number of comorbidities, most notably type 2 diabetes and hypertension, as well as elevated all-cause mortality. The treatment for obesity and its associated comorbidities has most recently expanded into the field of bariatric endoscopy. This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Because of its minimally invasive nature, bariatric endoscopic therapy has the potential to appeal to the large sector of the obese population that resists surgery, as well as those early in the onset of obesity. To date, five endoscopic devices have been approved by the U.S. Food and Drug Administration for the treatment of obesity, and many more are in development, undergoing clinical trials, or being used around the world. Here, we present the current state of the field, highlight recent developments, and describe the clinical outcomes of these minimally invasive procedures in terms of weight loss, improvement in metabolic profile, and reduction in comorbidities.

KW - aspiration therapy

KW - endoscopic sleeve gastroplasty

KW - gastrointestinal bypass sleeve

KW - intragastric balloon

KW - primary obesity surgery endoluminal

KW - transoral gastroplasty

UR - http://www.scopus.com/inward/record.url?scp=85044151578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044151578&partnerID=8YFLogxK

U2 - 10.1111/nyas.13441

DO - 10.1111/nyas.13441

M3 - Review article

C2 - 28884820

AN - SCOPUS:85044151578

VL - 1411

SP - 36

EP - 52

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -